Amendments to the Specification:

Please amend the paragraph at page 1, line 1 as follows.

Cross-Reference to Related Applications

This application is a continuation of U.S. Application Serial No. 09/563,286, filed May 3, 2000, now pending, which is a continuation-in-part of U. S. Application Serial No. 09/428,082, filed October 22, 1999, now U.S. Pat. No. 6,660,843, which claims the benefit of United States Provisional application 60/105,371, filed October 23, 1998, which are incorporated by reference herein.

Please amend the Abstract at page 139, lines 5-20 as follows.

The present invention concerns fusion of Fc domains with biologically active Ang-2 binding peptides and a process for preparing pharmaceutical agents using such biologically active peptides. ~~In this invention, pharmacologically active compounds are prepared by a process comprising:~~

~~a) selecting at least one peptide that modulates the activity of a protein of interest; and~~

~~b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide.~~

Linkage to the ~~vehicle~~ Fc domain increases the half-life of the peptide, which otherwise would be quickly degraded *in vivo*. ~~The preferred vehicle is an Fc domain.~~ The peptide can be selected, for example, by phage display, *E. coli* display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.